Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has received a consensus broker rating score of 1.75 (Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company.

Brokerages have set a 1-year consensus target price of $31.25 for the company, according to Zacks. Zacks has also given Rhythm Pharmaceuticals an industry rank of 101 out of 265 based on the ratings given to related companies.

A number of equities research analysts have weighed in on RYTM shares. Morgan Stanley started coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set an “equal weight” rating and a $23.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price target on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 14th. Bank of America started coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Cowen started coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set an “outperform” rating and a $40.00 price target on the stock.

Shares of Rhythm Pharmaceuticals (NASDAQ RYTM) opened at $28.04 on Friday. Rhythm Pharmaceuticals has a 52 week low of $21.38 and a 52 week high of $33.81.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($1.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($1.38). equities research analysts anticipate that Rhythm Pharmaceuticals will post -1.63 earnings per share for the current year.

In related news, major shareholder S.A. Ipsen acquired 20,000 shares of the business’s stock in a transaction on Tuesday, October 10th. The stock was bought at an average cost of $17.00 per share, with a total value of $340,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David P. Meeker acquired 25,000 shares of the business’s stock in a transaction on Tuesday, October 10th. The shares were bought at an average cost of $17.00 per share, with a total value of $425,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 1,285,000 shares of company stock valued at $21,845,000.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/15/zacks-rhythm-pharmaceuticals-inc-rytm-receives-average-recommendation-of-buy-from-brokerages.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.